Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

MLEC vs RKDA vs PGEN vs SLP vs BYND

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
MLEC
Moolec Science S.A.

Biotechnology

HealthcareNASDAQ • LU
Market Cap$7M
5Y Perf.-7.4%
RKDA
Arcadia Biosciences, Inc.

Agricultural Inputs

Basic MaterialsNASDAQ • US
Market Cap$2M
5Y Perf.-99.0%
PGEN
Precigen, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$1.22B
5Y Perf.-39.8%
SLP
Simulations Plus, Inc.

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$324M
5Y Perf.-74.6%
BYND
Beyond Meat, Inc.

Packaged Foods

Consumer DefensiveNASDAQ • US
Market Cap$414M
5Y Perf.-99.3%

MLEC vs RKDA vs PGEN vs SLP vs BYND — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
MLEC logoMLEC
RKDA logoRKDA
PGEN logoPGEN
SLP logoSLP
BYND logoBYND
IndustryBiotechnologyAgricultural InputsBiotechnologyMedical - Healthcare Information ServicesPackaged Foods
Market Cap$7M$2M$1.22B$324M$414M
Revenue (TTM)$8M$5M$6M$79M$265M
Net Income (TTM)$-8M$-2M$-247M$-64M$244M
Gross Margin-8.2%36.2%23.0%59.6%3.5%
Operating Margin-116.7%-51.4%-18.6%-89.2%-82.4%
Forward P/E18.0x
Total Debt$247M$0.00$6M$616K$508M
Cash & Equiv.$768K$259K$30M$31M$208M

MLEC vs RKDA vs PGEN vs SLP vs BYNDLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

MLEC
RKDA
PGEN
SLP
BYND
StockMar 21May 26Return
Moolec Science S.A. (MLEC)10092.6-7.4%
Arcadia Biosciences… (RKDA)1001.0-99.0%
Precigen, Inc. (PGEN)10060.2-39.8%
Simulations Plus, I… (SLP)10025.4-74.6%
Beyond Meat, Inc. (BYND)1000.7-99.3%

Price return only. Dividends and distributions are not included.

Quick Verdict: MLEC vs RKDA vs PGEN vs SLP vs BYND

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MLEC and BYND are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Beyond Meat, Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. PGEN also leads in specific categories worth noting. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
MLEC
Moolec Science S.A.
The Long-Run Compounder

MLEC carries the broadest edge in this set and is the clearest fit for long-term compounding.

  • -8.5% 10Y total return vs SLP's 104.0%
  • 58.3% revenue growth vs PGEN's -36.9%
  • Beta 0.89 vs BYND's 1.67
Best for: long-term compounding
RKDA
Arcadia Biosciences, Inc.
The Basic Materials Pick

RKDA lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: basic materials exposure
PGEN
Precigen, Inc.
The Momentum Pick

PGEN ranks third and is worth considering specifically for momentum.

  • +207.4% vs RKDA's -74.4%
Best for: momentum
SLP
Simulations Plus, Inc.
The Income Pick

SLP is the clearest fit if your priority is income & stability and growth exposure.

  • Dividend streak 4 yrs, beta 1.25
  • Rev growth 13.1%, EPS growth -7.6%, 3Y rev CAGR 13.7%
  • Lower volatility, beta 1.25, Low D/E 0.5%, current ratio 7.67x
  • Beta 1.25, current ratio 7.67x
Best for: income & stability and growth exposure
BYND
Beyond Meat, Inc.
The Quality Compounder

BYND is the #2 pick in this set and the best alternative if quality and efficiency is your priority.

  • 92.2% margin vs PGEN's -39.1%
  • 39.3% ROA vs PGEN's -144.1%, ROIC -44.4% vs -152.8%
Best for: quality and efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthMLEC logoMLEC58.3% revenue growth vs PGEN's -36.9%
Quality / MarginsBYND logoBYND92.2% margin vs PGEN's -39.1%
Stability / SafetyMLEC logoMLECBeta 0.89 vs BYND's 1.67
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)PGEN logoPGEN+207.4% vs RKDA's -74.4%
Efficiency (ROA)BYND logoBYND39.3% ROA vs PGEN's -144.1%, ROIC -44.4% vs -152.8%

MLEC vs RKDA vs PGEN vs SLP vs BYND — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

MLECMoolec Science S.A.

Segment breakdown not available.

RKDAArcadia Biosciences, Inc.
FY 2025
Product
100.0%$5M
PGENPrecigen, Inc.
FY 2024
Exemplar Segment
100.0%$4M
SLPSimulations Plus, Inc.
FY 2025
License and Maintenance
57.9%$46M
Service
42.1%$33M
BYNDBeyond Meat, Inc.
FY 2025
Reporting Segment
100.0%$275M

MLEC vs RKDA vs PGEN vs SLP vs BYND — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLSLPLAGGINGBYND

Income & Cash Flow (Last 12 Months)

SLP leads this category, winning 3 of 6 comparable metrics.

BYND is the larger business by revenue, generating $265M annually — 54.5x RKDA's $5M. BYND is the more profitable business, keeping 92.2% of every revenue dollar as net income compared to PGEN's -39.1%. On growth, MLEC holds the edge at +9.5% YoY revenue growth, suggesting stronger near-term business momentum.

MetricMLEC logoMLECMoolec Science S.…RKDA logoRKDAArcadia Bioscienc…PGEN logoPGENPrecigen, Inc.SLP logoSLPSimulations Plus,…BYND logoBYNDBeyond Meat, Inc.
RevenueTrailing 12 months$8M$5M$6M$79M$265M
EBITDAEarnings before interest/tax-$8M-$2M-$115M-$63M-$187M
Net IncomeAfter-tax profit-$8M-$2M-$247M-$64M$244M
Free Cash FlowCash after capex-$6M-$5M-$76M$23M-$134M
Gross MarginGross profit ÷ Revenue-8.2%+36.2%+23.0%+59.6%+3.5%
Operating MarginEBIT ÷ Revenue-116.7%-51.4%-18.6%-89.2%-82.4%
Net MarginNet income ÷ Revenue-105.7%-48.1%-39.1%-81.7%+92.2%
FCF MarginFCF ÷ Revenue-78.1%-97.6%-12.0%+29.2%-50.6%
Rev. Growth (YoY)Latest quarter vs prior year+9.5%-25.9%+2.1%-2.7%-15.3%
EPS Growth (YoY)Latest quarter vs prior year-20.0%+16.9%-11.7%+2.3%+90.9%
SLP leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

Evenly matched — MLEC and RKDA and PGEN each lead in 1 of 3 comparable metrics.
MetricMLEC logoMLECMoolec Science S.…RKDA logoRKDAArcadia Bioscienc…PGEN logoPGENPrecigen, Inc.SLP logoSLPSimulations Plus,…BYND logoBYNDBeyond Meat, Inc.
Market CapShares × price$7M$2M$1.2B$324M$414M
Enterprise ValueMkt cap + debt − cash$253M$1M$1.2B$293M$714M
Trailing P/EPrice ÷ TTM EPS-0.03x-0.64x-8.83x-4.99x-0.49x
Forward P/EPrice ÷ next-FY EPS est.18.01x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple21.45x
Price / SalesMarket cap ÷ Revenue0.02x0.31x309.66x4.09x1.50x
Price / BookPrice ÷ Book value/share0.36x28.85x2.59x
Price / FCFMarket cap ÷ FCF18.58x
Evenly matched — MLEC and RKDA and PGEN each lead in 1 of 3 comparable metrics.

Profitability & Efficiency

SLP leads this category, winning 3 of 9 comparable metrics.

RKDA delivers a -40.6% return on equity — every $100 of shareholder capital generates $-41 in annual profit, vs $-6 for PGEN. SLP carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to PGEN's 0.14x. On the Piotroski fundamental quality scale (0–9), SLP scores 6/9 vs RKDA's 2/9, reflecting solid financial health.

MetricMLEC logoMLECMoolec Science S.…RKDA logoRKDAArcadia Bioscienc…PGEN logoPGENPrecigen, Inc.SLP logoSLPSimulations Plus,…BYND logoBYNDBeyond Meat, Inc.
ROE (TTM)Return on equity-150.9%-40.6%-5.9%-50.5%
ROA (TTM)Return on assets-26.6%-26.1%-144.1%-46.6%+39.3%
ROICReturn on invested capital-8.8%-2.5%-152.8%-39.6%-44.4%
ROCEReturn on capital employed-129.5%-107.2%-44.1%-40.3%
Piotroski ScoreFundamental quality 0–942363
Debt / EquityFinancial leverage0.14x0.00x
Net DebtTotal debt minus cash$246M-$259,000-$24M-$30M$300M
Cash & Equiv.Liquid assets$767,919$259,000$30M$31M$208M
Total DebtShort + long-term debt$247M$0$6M$616,000$508M
Interest CoverageEBIT ÷ Interest expense-2.94x-273.83x-11.47x
SLP leads this category, winning 3 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

PGEN leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in MLEC five years ago would be worth $9,201 today (with dividends reinvested), compared to $81 for BYND. Over the past 12 months, PGEN leads with a +207.4% total return vs RKDA's -74.4%. The 3-year compound annual growth rate (CAGR) favors PGEN at 49.2% vs BYND's -59.1% — a key indicator of consistent wealth creation.

MetricMLEC logoMLECMoolec Science S.…RKDA logoRKDAArcadia Bioscienc…PGEN logoPGENPrecigen, Inc.SLP logoSLPSimulations Plus,…BYND logoBYNDBeyond Meat, Inc.
YTD ReturnYear-to-date+3153.6%-48.8%-3.0%-11.3%+1.3%
1-Year ReturnPast 12 months-2.0%-74.4%+207.4%-44.6%-64.9%
3-Year ReturnCumulative with dividends-70.1%-82.8%+232.0%-59.6%-93.1%
5-Year ReturnCumulative with dividends-8.0%-98.9%-36.5%-70.5%-99.2%
10-Year ReturnCumulative with dividends-8.5%-99.9%-84.6%+104.0%-98.6%
CAGR (3Y)Annualised 3-year return-33.1%-44.4%+49.2%-26.0%-59.1%
PGEN leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — MLEC and PGEN each lead in 1 of 2 comparable metrics.

MLEC is the less volatile stock with a 0.89 beta — it tends to amplify market swings less than BYND's 1.67 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PGEN currently trades 79.3% from its 52-week high vs BYND's 11.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricMLEC logoMLECMoolec Science S.…RKDA logoRKDAArcadia Bioscienc…PGEN logoPGENPrecigen, Inc.SLP logoSLPSimulations Plus,…BYND logoBYNDBeyond Meat, Inc.
Beta (5Y)Sensitivity to S&P 5000.89x0.98x1.44x1.25x1.67x
52-Week HighHighest price in past year$23.22$6.71$5.23$34.01$7.69
52-Week LowLowest price in past year$0.20$1.01$1.23$11.09$0.50
% of 52W HighCurrent price vs 52-week peak+38.7%+16.4%+79.3%+47.2%+11.6%
RSI (14)Momentum oscillator 0–10051.342.362.767.960.7
Avg Volume (50D)Average daily shares traded319K35K4.3M315K59.5M
Evenly matched — MLEC and PGEN each lead in 1 of 2 comparable metrics.

Analyst Outlook

SLP leads this category, winning 1 of 1 comparable metric.

Analyst consensus: PGEN as "Buy", SLP as "Buy", BYND as "Sell". Consensus price targets imply 4889.9% upside for BYND (target: $45) vs 44.6% for PGEN (target: $6).

MetricMLEC logoMLECMoolec Science S.…RKDA logoRKDAArcadia Bioscienc…PGEN logoPGENPrecigen, Inc.SLP logoSLPSimulations Plus,…BYND logoBYNDBeyond Meat, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuySell
Price TargetConsensus 12-month target$6.00$56.00$44.55
# AnalystsCovering analysts16821
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises14
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+14.2%0.0%0.0%0.0%0.0%
SLP leads this category, winning 1 of 1 comparable metric.
Key Takeaway

SLP leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PGEN leads in 1 (Total Returns). 2 tied.

Best OverallSimulations Plus, Inc. (SLP)Leads 3 of 6 categories
Loading custom metrics...

MLEC vs RKDA vs PGEN vs SLP vs BYND: Key Questions Answered

9 questions · data-driven answers · updated daily

01

Is MLEC or RKDA or PGEN or SLP or BYND a better buy right now?

For growth investors, Moolec Science S.

A. (MLEC) is the stronger pick with 58. 3% revenue growth year-over-year, versus -36. 9% for Precigen, Inc. (PGEN). Analysts rate Precigen, Inc. (PGEN) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — MLEC or RKDA or PGEN or SLP or BYND?

Over the past 5 years, Moolec Science S.

A. (MLEC) delivered a total return of -8. 0%, compared to -99. 2% for Beyond Meat, Inc. (BYND). Over 10 years, the gap is even starker: SLP returned +104. 0% versus RKDA's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — MLEC or RKDA or PGEN or SLP or BYND?

By beta (market sensitivity over 5 years), Moolec Science S.

A. (MLEC) is the lower-risk stock at 0. 89β versus Beyond Meat, Inc. 's 1. 67β — meaning BYND is approximately 89% more volatile than MLEC relative to the S&P 500. On balance sheet safety, Simulations Plus, Inc. (SLP) carries a lower debt/equity ratio of 0% versus 14% for Precigen, Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — MLEC or RKDA or PGEN or SLP or BYND?

By revenue growth (latest reported year), Moolec Science S.

A. (MLEC) is pulling ahead at 58. 3% versus -36. 9% for Precigen, Inc. (PGEN). On earnings-per-share growth, the picture is similar: Arcadia Biosciences, Inc. grew EPS 66. 9% year-over-year, compared to -89. 8% for Moolec Science S. A.. Over a 3-year CAGR, SLP leads at 13. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — MLEC or RKDA or PGEN or SLP or BYND?

Beyond Meat, Inc.

(BYND) is the more profitable company, earning 79. 8% net margin versus -32. 2% for Precigen, Inc. — meaning it keeps 79. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MLEC leads at -3. 1% versus -34. 4% for PGEN. At the gross margin level — before operating expenses — SLP leads at 58. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is MLEC or RKDA or PGEN or SLP or BYND more undervalued right now?

Analyst consensus price targets imply the most upside for BYND: 4889.

9% to $44. 55.

07

Which pays a better dividend — MLEC or RKDA or PGEN or SLP or BYND?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

08

Is MLEC or RKDA or PGEN or SLP or BYND better for a retirement portfolio?

For long-horizon retirement investors, Moolec Science S.

A. (MLEC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 89)). Beyond Meat, Inc. (BYND) carries a higher beta of 1. 67 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MLEC: -8. 5%, BYND: -98. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between MLEC and RKDA and PGEN and SLP and BYND?

These companies operate in different sectors (MLEC (Healthcare) and RKDA (Basic Materials) and PGEN (Healthcare) and SLP (Healthcare) and BYND (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MLEC is a small-cap high-growth stock; RKDA is a small-cap quality compounder stock; PGEN is a small-cap quality compounder stock; SLP is a small-cap quality compounder stock; BYND is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

MLEC

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 474%
Run This Screen
Stocks Like

RKDA

Quality Business

  • Sector: Basic Materials
  • Market Cap > $100B
  • Gross Margin > 21%
Run This Screen
Stocks Like

PGEN

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 103%
  • Gross Margin > 13%
Run This Screen
Stocks Like

SLP

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 35%
Run This Screen
Stocks Like

BYND

Quality Mega-Cap Compounder

  • Sector: Consumer Defensive
  • Market Cap > $100B
  • Net Margin > 55%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform MLEC and RKDA and PGEN and SLP and BYND on the metrics below

Revenue Growth>
%
(MLEC: 948.3% · RKDA: -25.9%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.